<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Amphotericin B lipid complex: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Amphotericin B lipid complex: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Amphotericin B lipid complex: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11497" href="/d/html/11497.html" rel="external">see "Amphotericin B lipid complex: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12660" href="/d/html/12660.html" rel="external">see "Amphotericin B lipid complex: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F134818"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Abelcet</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865918"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Abelcet</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F134840"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antifungal Agent, Parenteral</li></ul></div>
<div class="block doa drugH1Div" id="F134822"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>Formulation: </b>Lipid-based amphotericin formulations (Abelcet) may be confused with conventional formulations (deoxycholate [Amphocin, Fungizone]) or with other lipid-based amphotericin formulations (amphotericin B liposomal [AmBisome]; amphotericin B cholesteryl sulfate complex [Amphotec]). Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. <b>Premedication:</b> To minimize infusion-related immediate reactions, premedicate with the following 30 to 60 minutes prior to administration: Acetaminophen, diphenhydramine, and/<b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4','lexi-content-ref-19196219','lexi-content-ref-8838189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4','lexi-content-ref-19196219','lexi-content-ref-8838189'])">Ref</a></span>). Pre-infusion administration of 1 L of NS may reduce the risk of nephrotoxicity during amphotericin B treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88c58fcb-77ef-4148-803b-f83c6e2aa28b">Aspergillosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis, invasive (including disseminated and extrapulmonary) (alternative agent): IV:</b> 5 mg/kg once daily; minimum duration of treatment is 6 to 12 weeks and depends on site of infection, extent of disease, and level/duration of immunosuppression. <b>Note:</b> Amphotericin B lipid complex should be reserved as salvage therapy for those intolerant of or refractory to preferred agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27365388'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b66180c1-9659-486b-b77b-bdb1c4096776">Blastomycosis, moderately severe to severe, non-CNS disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blastomycosis, moderately severe to severe, non-CNS disease:</b>
<b>IV:</b> 3 to 5 mg/kg once daily for 1 to 2 weeks or until improvement, followed by oral itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18462107'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Candidemia (neutropenic and nonneutropenic patients), including disseminated candidiasis (alternative agent):</i>
<b>IV:</b> 3 to 5 mg/kg once daily. Total duration (including oral step-down therapy) is ≥14 days after first negative blood culture and continues until signs/symptoms of candidemia and neutropenia, if present, have resolved; metastatic complications warrant a longer duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cardiac device infection (including implantable cardiac defibrillator, pacemaker, ventricular assist device):</i>
<b>IV:</b> 3 to 5 mg/kg once daily, with or without flucytosine; step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures; total antifungal duration is ≥4 weeks after device removal for isolated generator pocket infection and ≥6 weeks after device removal for wire infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic disseminated (hepatosplenic):</i>
<b>IV:</b> 3 to 5 mg/kg once daily for several weeks, followed by oral azole step-down therapy until lesion resolution and through periods of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric therapy, suspected invasive candidiasis (nonneutropenic ICU patients) (alternative agent): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Antifungal therapy is not routinely warranted for initial management of nonneutropenic patients with sepsis. Consider use for critically ill patients with unexplained fever or unexplained hypotension despite broad-spectrum antimicrobial therapy and risk factors for invasive candidiasis (eg, indwelling venous catheter, hemodialysis, trauma or burns, recent surgery, parenteral nutrition) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628','lexi-content-ref-34599691','lexi-content-ref-Vazquez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628','lexi-content-ref-34599691','lexi-content-ref-Vazquez.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 3 to 5 mg/kg once daily. For those who improve, continue empiric antifungal therapy for 2 weeks; consider discontinuing after 4 to 5 days in patients with no evidence of invasive candidiasis and no clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endocarditis, native or prosthetic valve:</i>
<b> IV:</b> 3 to 5 mg/kg once daily, with or without flucytosine; step down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures. Total antifungal duration is ≥6 weeks after valve replacement surgery, with longer duration for perivalvular abscesses, other complications, or a nonsurgical approach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Esophageal, refractory disease (alternative agent) (off-label use): </i>
<b>Note:</b> Reserve use for patients who have inadequate response to or who are unable to take other agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>3 mg/kg/day. Transition to an oral antifungal once patient tolerates oral intake if susceptibility allows; total antifungal duration is 14 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-Kauffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-Kauffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Intra-abdominal infection (eg, peritonitis, abdominal abscess) (alternative agent):</i>
<b> IV:</b> 3 to 5 mg/kg once daily. Duration of therapy depends on source control and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Osteoarticular infection (osteomyelitis or septic arthritis) (alternative agent):</i>
<b>IV:</b> 3 to 5 mg/kg once daily for ≥2 weeks, followed by fluconazole. Total duration of therapy (including oral step-down therapy) is 6 to 12 months for osteomyelitis and ≥6 weeks for septic arthritis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Thrombophlebitis, suppurative:</i>
<b>IV:</b> 3 to 5 mg/kg once daily; continue antifungal therapy until catheter removed and thrombus resolved, and for ≥2 weeks after candidemia (if present) has cleared (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fb5d76c-3366-4cef-be06-02cc83aaddac">Coccidioidomycosis, severe, nonmeningeal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis, severe, nonmeningeal infection:</b>
<b>IV:</b> 3 to 5 mg/kg once daily until clinical improvement, then switch to an oral azole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-HHS.4','lexi-content-ref-27470238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-HHS.4','lexi-content-ref-27470238'])">Ref</a></span>). <b>Note</b>: Some experts suggest initiating the oral azole at the same time as amphotericin B lipid complex and continuing the oral azole when amphotericin B lipid complex is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fde3ff9-c889-4d02-a89e-e555f9474732">Cryptococcal meningoencephalitis, disseminated disease, or severe pulmonary infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcal meningoencephalitis, disseminated disease, or severe pulmonary infection (alternative agent in patients with HIV):</b> Induction therapy: <b>IV:</b> 5 mg/kg once daily in combination with flucytosine (or fluconazole if flucytosine cannot be used) for ≥2 weeks, followed by consolidation therapy with oral fluconazole. Duration of induction therapy may be extended in patients who cannot use combination therapy or who have evidence of neurological complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cox.1','lexi-content-ref-HHS.4','lexi-content-ref-20047480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cox.1','lexi-content-ref-HHS.4','lexi-content-ref-20047480'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6562281-2fa6-4b61-86f8-13a170c56142">Fusariosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fusariosis, invasive: IV:</b> 3 to 5 mg/kg once daily; duration of treatment is often prolonged and depends on the site of infection, severity, immune status, and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nucci.1','lexi-content-ref-15809926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nucci.1','lexi-content-ref-15809926'])">Ref</a></span>). <b>Note:</b> Some experts suggest combination antifungal therapy for patients with severe immunosuppression, severe disease, or increasing skin lesions or persistently positive blood cultures with monotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nucci.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nucci.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="da0b3cae-9a59-4ae8-9ed2-c6aad13abf2e">Histoplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Histoplasmosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Moderately severe to severe pulmonary or disseminated disease in immunocompetent patients or solid organ transplant recipients:</i>
<b>IV:</b> 5 mg/kg once daily for 1 to 2 weeks, followed by oral itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-17806045']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-17806045'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Moderately severe to severe disseminated disease in patients with HIV (alternative agent):</i>
<b> IV:</b> 5 mg/kg once daily for ≥2 weeks, followed by oral itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed727c2e-50ad-4916-9de0-8aa740ea0c6a">Leishmaniasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis (visceral) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with HIV:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment (alternative agent): </i>
<b>IV:</b> 2 to 4 mg/kg once daily <b>or</b> an interrupted schedule of 4 mg/kg on days 1 to 5, and on days 10, 17, 24, 31, and 38 to achieve a total dose of 20 to 60 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Chronic maintenance therapy (for patients with a CD4 count &lt;200 cells/mm<sup>3</sup>):</i>
<b>IV:</b> 3 mg/kg every 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunocompetent patients:</i>
<b>IV:</b> 2 to 3 mg/kg once daily for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunosuppressed patients: </i>
<b>IV:</b> 3 to 5 mg/kg once daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6cb02bb-5399-4d63-aff5-c4b202170424">Mucormycosis, invasive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucormycosis, invasive (without CNS involvement): Note:</b> Prompt surgical debridement is often needed to achieve clinical cure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 to 10 mg/kg once daily; may step down to oral therapy (eg, isavuconazole, posaconazole) based on patient response. Total duration (including oral step-down therapy) varies based on clinical and radiologic response and patient immune status; several months are often warranted, with some patients requiring lifelong therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664','lexi-content-ref-15809926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664','lexi-content-ref-15809926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4b4cc183-e762-44d3-9d4d-6ff926a219f3">Neutropenic fever, empiric antifungal therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neutropenic fever, empiric antifungal therapy (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Recommended for patients with persistent or recurrent fever after ≥4 days of antimicrobial therapy when the duration of neutropenia is expected to exceed 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21258094','lexi-content-ref-27365388']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21258094','lexi-content-ref-27365388'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 5 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11073745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11073745'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3eb7406-2279-4fb2-ad39-e978257861e9">Sporotrichosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sporotrichosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Meningeal infection:</i>
<b>IV:</b> 5 mg/kg once daily for 4 to 6 weeks, followed by oral itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary, osteoarticular, and disseminated infection:</i>
<b>IV:</b> 3 to 5 mg/kg once daily, followed by oral itraconazole after a favorable response is seen with amphotericin initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991910"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Manufacturer's labeling:</i> No dosage adjustment provided in manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Alternate recommendations </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>)<i>:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent hemodialysis: Not hemodialyzable; no supplemental dosage necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: No supplemental dosage necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CRRT: No supplemental dosage necessary.</p></div>
<div class="block doha drugH1Div" id="F50989167"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doo drugH1Div" id="F55170346"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Class 1, 2, or 3 obesity (BMI ≥30 kg/m<sup>2</sup>): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> No dosage adjustment necessary. Use <b>actual body weight</b> for weight-based dose calculations; however, a maximum daily dose of 500 mg is recommended (recommendation extrapolated from a study of a similar product (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31588493','lexi-content-ref-expert.doo']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31588493','lexi-content-ref-expert.doo'])">Ref</a></span>)). Due to higher doses, dosing using actual body weight may be associated with increased toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Amsden.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Amsden.1'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rationale for recommendations:</b> There are sparse data describing the effect of obesity on dosing requirements for polyene antifungals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Amsden.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Amsden.1'])">Ref</a></span>). There are no human pharmacokinetic studies for amphotericin B (lipid complex) in subjects with obesity. Amphotericin B (lipid complex) has a high V<sub>d</sub> (131 to 147 L/kg), although distribution into adipose tissue is likely limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Amsden.1','lexi-content-ref-11801578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Amsden.1','lexi-content-ref-11801578'])">Ref</a></span>). There are no data correlating V<sub>d</sub> with body weight, and one pharmacokinetic study with a different lipid formulation of amphotericin B found no relationship between clearance and weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31588493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31588493'])">Ref</a></span>). There are no data supporting one weight metric over another.</p></div>
<div class="block doe drugH1Div" id="F134823"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F134834"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12660" href="/d/html/12660.html" rel="external">see "Amphotericin B lipid complex: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet, Amphotec, AmBisome) and conventional amphotericin B for injection.</b> Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> To minimize infusion-related immediate reactions, may premedicate with the following 30 to 60 minutes prior to administration: Acetaminophen, diphenhydramine, and/or hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered. Adequate hydration and pre-infusion administration of NS may reduce the risk of nephrotoxicity during amphotericin B treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-AAP.1','lexi-content-ref-9303390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-AAP.1','lexi-content-ref-9303390'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="11922a6f-52e3-4d48-8959-25f730e3f929">Aspergillosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspergillosis</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Invasive:</i> Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily; minimum duration of treatment is 6 to 12 weeks and depends on site of infection, extent of disease, and level/duration of immunosuppression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11305476','lexi-content-ref-27365388','lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11305476','lexi-content-ref-27365388','lexi-content-ref-28203777'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endocarditis:</i> Children and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="90ff3b27-4e8f-490e-a6d4-4a1a6aab3eca">Blastomycosis, moderately severe to severe disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Blastomycosis, moderately severe to severe disease:</b> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily for 1 to 2 weeks or until improvement, followed by oral itraconazole for a total of 12 months. For CNS disease, initial IV therapy at the top end of the range (5 mg/kg/dose) is recommended for 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18462107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18462107'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a474b86d-f618-403c-abc4-11a9a731c6ce">Candidiasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Candidiasis</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Invasive (alternative agent):</i> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily. Duration of therapy should be individualized based on clinical response and presence of deep-tissue foci; candidemia should be treated for ≥14 days from the first negative blood culture and clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26679628'])">Ref</a></span>). <b>Note:</b> In patients with HIV, consider doses at the higher end of the range (5 mg/kg/dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Endocarditis</i>: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine. Step-down to azole therapy in clinically stable patients with susceptible isolates and negative repeat cultures. Total antifungal duration is ≥6 weeks after valve replacement surgery, with longer duration for perivalvular abscess, other complications, or a nonsurgical approach (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317','lexi-content-ref-26679628']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317','lexi-content-ref-26679628'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Esophageal (alternative agent):</i> Adolescents with HIV: IV: 3 to 4 mg/kg/dose once daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Ventriculitis or meningitis, health care-associated: </i>Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily with or without flucytosine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28203777']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28203777'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fb5d76c-3366-4cef-be06-02cc83aaddac">Coccidioidomycosis, severe, nonmeningeal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Coccidioidomycosis, severe, nonmeningeal infection:</b> Patients with HIV:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: IV: 5 mg/kg/dose once daily until clinical improvement, then switch to an oral azole to complete ≥12 months of therapy. Dose may be increased to as high as 10 mg/kg/dose once daily for life-threatening infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: IV: 3 to 5 mg/kg/dose once daily until clinical improvement, then switch to an oral azole to complete ≥12 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>). <b>Note: </b>Some experts suggest initiating the oral azole in combination with the amphotericin B product and then continuing the oral azole when amphotericin B is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7fde3ff9-c889-4d02-a89e-e555f9474732">Cryptococcal meningoencephalitis, disseminated disease, or severe pulmonary infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cryptococcal </b>
<b>meningoencephalitis, disseminated disease, or severe pulmonary infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Induction therapy: IV: 5 mg/kg/dose once daily as part of appropriate combination therapy for ≥2 weeks, followed by consolidation therapy with oral fluconazole. Induction therapy duration may be extended in patients who cannot receive combination therapy, who are clinically deteriorating, if CNS cultures remain positive, or if neurological complications are present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30900315','lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-20047480','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30900315','lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-20047480','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0924111-ba3a-4a6a-936e-b3b81bc40013">Histoplasmosis, moderately severe to severe pulmonary or disseminated disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Histoplasmosis, moderately severe to severe pulmonary or disseminated disease (non-CNS):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily for 1 to 2 weeks and until clinical improvement, followed by oral itraconazole therapy. For patients with HIV, consider treating ≥2 weeks before transition to oral therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30924967','lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-17806045','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30924967','lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-17806045','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c5910cba-943b-4cb9-9bf3-c1e295445215">Leishmaniasis, visceral</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leishmaniasis, visceral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunocompetent patients (alternative agent): </i>Infants, Children, and Adolescents: IV: 2 to 3 mg/kg/dose once daily for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immunocompromised patients (alternative agent): </i>Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27941143']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27941143'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with HIV: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Treatment (alternative agent): Adolescents: IV: 2 to 4 mg/kg/dose once daily <b>or</b> an interrupted schedule of 4 mg/kg/dose on days 1 to 5, and on days 10, 17, 24, 31, and 38 to achieve a total dose of 20 to 60 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic maintenance therapy (for patients with a CD4 count &lt;200 cells/mm<sup>3</sup>): Adolescents: IV: 3 mg/kg/dose every 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cbcc0f30-1339-4971-b9a9-1b3af0f3574f">Mucormycosis, invasive, without CNS involvement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mucormycosis, invasive, without CNS involvement:</b> Limited data available: <b>Note:</b> Prompt surgical debridement is often needed to achieve clinical cure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily. Total duration (including oral step-down therapy if possible) varies based on clinical and radiologic response and patient immune status; several months are often warranted, with some patients requiring lifelong therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31699664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31699664'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3eb7406-2279-4fb2-ad39-e978257861e9">Sporotrichosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sporotrichosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Meningeal infection</i>: Adolescents: IV: 5 mg/kg/dose once daily for 4 to 6 weeks, followed by oral itraconazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pulmonary, osteoarticular, and disseminated infection</i>: Adolescents: IV: 3 to 5 mg/kg/dose once daily, followed by oral itraconazole after a favorable response is seen with amphotericin initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968818']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968818'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51064813"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's recommendations: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Alternate recommendations: The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: No supplemental dosage necessary</p>
<p style="text-indent:-2em;margin-left:6em;">Peritoneal dialysis: No supplemental dosage necessary</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous renal replacement therapy (CRRT): No supplemental dosage necessary</p></div>
<div class="block dohp drugH1Div" id="F51064814"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F134792"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (14%), multi-organ failure (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (3%), hypertension (5%), hypotension (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (4%), diarrhea (6%), gastrointestinal hemorrhage (4%), nausea (9%), vomiting (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (4%), leukopenia (4%), thrombocytopenia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hyperbilirubinemia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Sepsis (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (6%), pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (7%), respiratory failure (8%), respiratory system disorder (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cardiac arrhythmia (including ventricular fibrillation) cardiomyopathy, heart failure, pulmonary embolism, shock, thrombophlebitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, exfoliative dermatitis, maculopapular rash, pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Acidosis, hypercalcemia, hyperglycemia, hyperkalemia, hyperuricemia, hypocalcemia, hypoglycemia, hypophosphatemia, increased lactate dehydrogenase, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, cholangitis, cholecystitis, dyspepsia, epigastric pain, increased serum amylase, melena, stomach cramps</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anuria, dysuria, impotence, oliguria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Disorder of hemostatic component of blood, hematologic disease (including eosinophilia), leukocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Acute hepatic failure, hepatic sinusoidal obstruction syndrome, hepatitis, hepatomegaly, jaundice</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including nonimmune anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including inflammation at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebrovascular accident, encephalopathy, extrapyramidal reaction, malaise, myasthenia, peripheral neuropathy, seizure, vertigo (transient)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Diplopia, visual impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness, hearing loss, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen, renal insufficiency, renal tubular acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, bronchospasm, hemoptysis, pleural effusion, pulmonary edema, tachypnea, wheezing</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypomagnesemia (Malani 2005)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (including increased serum alanine aminotransferase, increased alkaline phosphatase, increased serum aspartate aminotransferase) (Moghnieh 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (Moghnieh 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (Safdar 2010)</p></div>
<div class="block coi drugH1Div" id="F134805"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to amphotericin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F134789"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; during the initial dosing, the drug should be administered under close clinical observation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Acute reactions (including fever and chills) may occur 1-2 hours after starting an intravenous infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. Infusion has been rarely associated with hypotension, bronchospasm, arrhythmias, and shock.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Disease-related concerns</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antineoplastics: Concurrent use with antineoplastic agents may enhance the potential for renal toxicity, bronchospasm or hypotension; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxic drugs: Concurrent use of amphotericin B with other nephrotoxic drugs may enhance the potential for drug-induced renal toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Leukocyte transfusions: Acute pulmonary toxicity has been reported in patients receiving leukocyte transfusions and amphotericin B; amphotericin B lipid complex and concurrent leukocyte transfusions are not recommended.</p></div>
<div class="block foc drugH1Div" id="F134799"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abelcet: 5 mg/mL (20 mL)</p></div>
<div class="block geq drugH1Div" id="F134785"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322988"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (Abelcet Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg/mL (per mL): $6.30</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865919"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Abelcet: 5 mg/mL (20 mL)</p></div>
<div class="block adm drugH1Div" id="F134802"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> To minimize infusion-related immediate reactions, premedicate with the following 30 to 60 minutes prior to administration: Acetaminophen, diphenhydramine, and/<b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4','lexi-content-ref-19196219','lexi-content-ref-8838189']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4','lexi-content-ref-19196219','lexi-content-ref-8838189'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Administer at an infusion rate of 2.5 mg/kg/hour (eg, over 2 hours for 5 mg/kg). May prolong infusion over &gt;2 hours if necessary to reduce infusion-related reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21888451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21888451'])">Ref</a></span>). Invert infusion container several times prior to administration and every 2 hours during infusion if it exceeds 2 hours. <b>Do not use an in-line filter during administration.</b> Flush line with dextrose; normal saline may cause precipitate.</p>
<p style="text-indent:-2em;margin-left:2em;">Pre-infusion administration of 1 L of NS may reduce the risk of nephrotoxicity during amphotericin B treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.4']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.4'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612233"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">To minimize infusion-related immediate reactions, may premedicate with the following 30 to 60 minutes prior to administration: Acetaminophen, diphenhydramine, and/or hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered. Adequate hydration and pre-infusion administration of NS may reduce the risk of nephrotoxicity during amphotericin B treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-AAP.1','lexi-content-ref-9303390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2','lexi-content-ref-HHS.3','lexi-content-ref-AAP.1','lexi-content-ref-9303390'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: IV: Must be diluted prior to administration. Flush line with D5W prior to infusion. Gently shake the IV container of diluted drug to ensure that contents are thoroughly mixed, then administer at a rate of 2.5 mg/kg/hour (over 2 hours for 5 mg/kg/dose). <b>Do not use an in-line filter during administration.</b> If infusion time exceeds 2 hours, mix the contents by gently rotating the infusion bag every 2 hours.</p></div>
<div class="block use drugH1Div" id="F134801"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Fungal infection, invasive:</b> Treatment of invasive fungal infection in patients who are refractory to or intolerant of amphotericin B deoxycholate.</p></div>
<div class="block off-label drugH1Div" id="F45497823"><span class="drugH1">Use: Off-Label: Adult</span><p>Candidiasis, esophageal, refractory disease; Leishmaniasis, visceral; Neutropenic fever, empiric antifungal therapy</p></div>
<div class="block mst drugH1Div" id="F134847"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lipid-based amphotericin formulations (Abelcet) may be confused with conventional formulations (Fungizone) or with other lipid-based amphotericin formulations (amphotericin B liposomal [AmBisome]; amphotericin B cholesteryl sulfate complex [Amphotec]) </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298745"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F134793"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. Amphotericin B may enhance the neurotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arsenic Trioxide: Amphotericin B may enhance the hypotensive effect of Arsenic Trioxide. Amphotericin B may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as amphotericin B.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate.  Management: Avoid coadministration of colistimethate and amphotericin B whenever possible due to the potential for additive or synergistic nephrotoxicity. If coadministration cannot be avoided, closely monitor renal function.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Amphotericin B may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: Amphotericin B may enhance the hypokalemic effect of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. Amphotericin B may increase the serum concentration of Flucytosine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saccharomyces boulardii: Antifungal Agents (Systemic and Oral [Non-Absorbable]) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Amphotericin B may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13314059"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious, systemic fungal diseases in pregnant women, refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmus 2015).</p></div>
<div class="block brc drugH1Div" id="F134808"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if amphotericin is excreted into breast milk. Due to its poor oral absorption, systemic exposure to the nursing infant is expected to be decreased; however, because of the potential for toxicity, breastfeeding is not recommended by the manufacturer (Mactal-Haaf 2001).</p></div>
<div class="block dic drugH1Div" id="F14477892"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">If on parenteral nutrition, may need to adjust the amount of lipid infused. The lipid portion of amphotericin B (lipid complex) formulation contains 0.045 kcal per 5 mg (Sacks 1997).</p></div>
<div class="block mop drugH1Div" id="F134797"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BUN and serum creatinine levels should be determined every other day while therapy is increased and at least weekly thereafter. Renal function (monitor frequently during therapy), electrolytes (especially potassium and magnesium), liver function tests, temperature, PT/PTT, CBC; monitor input and output; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes, etc)</p></div>
<div class="block pha drugH1Div" id="F134788"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages.</p></div>
<div class="block phk drugH1Div" id="F134804"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Exhibits nonlinear kinetics; volume of distribution and clearance from blood increases with increasing dose.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: High tissue concentration found in the liver, spleen, and lung ; V<sub>d</sub>: Increases with higher doses (likely reflects increased uptake by tissues); 131 L/kg with 5 mg/kg/day</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 173 hours following multiple doses</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: 0.9% of dose excreted in urine over 24 hours; effects of hepatic and renal impairment on drug disposition are unknown</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Abelcet (amphotericin lipid complex) [prescribing information]. Indianapolis, IN: Exelead, Inc; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11207232">
<a name="11207232"></a>Adler-Shohet F, Waskin H, and Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2001;84(2):F131-F133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/11207232/pubmed" id="11207232" target="_blank">11207232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amsden.1">
<a name="Amsden.1"></a>Amsden JR, Slain D. Antifungal dosing in obesity: a review of the literature. <i>Curr Fungal Infect Rep</i>. 2011;5:83-91. doi:10.1007/s12281-011-0049-7</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941143">
<a name="27941143"></a>Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of Leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). <i>Clin Infect Dis</i>. 2016;63(12):1539-1557. doi: 10.1093/cid/ciw742.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/27941143/pubmed" id="27941143" target="_blank">27941143</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amsden.1">
<a name="Amsden.1"></a>Amsden JR, Slain D. Antifungal dosing in obesity: a review of the literature. <i>Curr Fungal Infect Rep</i>. 2011;5:83-91. doi:10.1007/s12281-011-0049-7</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18846390">
<a name="18846390"></a>Auron A, Auron-Gomez M, Raina R, Viswanathan S, Mhanna MJ. Effect of amphotericin B lipid complex (ABLC) in very low birth weight infants. <i>Pediatr Nephrol</i>. 2009;24(2):295-299. doi:10.1007/s00467-008-1017-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/18846390/pubmed" id="18846390" target="_blank">18846390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30900315">
<a name="30900315"></a>Baddley JW, Forrest GN; AST Infectious Diseases Community of Practice. Cryptococcosis in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant</i>. 2019;33(9):e13543. doi:10.1111/ctr.13543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/30900315/pubmed" id="30900315" target="_blank">30900315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis; Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21888451">
<a name="21888451"></a>Bassetti M, Aversa F, Ballerini F, et al. Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients. <i>Clin Drug Investig.</i> 2011;31(11):745-758. doi:10.2165/11593760-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/21888451/pubmed" id="21888451" target="_blank">21888451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>Candidiasis (Mucocutaneous). In: US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated May 26, 2020. Accessed June 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18462107">
<a name="18462107"></a>Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2008;46(12):1801-1812.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/18462107/pubmed" id="18462107" target="_blank">18462107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699664">
<a name="31699664"></a>Cornely OA, Alastruey-Izquierdo A, Arenz D, et al; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infect Dis</i>. 2019;19(12):e405-e421. doi:10.1016/S1473-3099(19)30312-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/31699664/pubmed" id="31699664" target="_blank">31699664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cox.1">
<a name="Cox.1"></a>Cox GM, Perfect JR. Cryptococcus neoformans: Treatment of meningoencephalitis and disseminated infection in patients without HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8089064">
<a name="8089064"></a>De Marie S, “Clinical Use of Liposomal and Lipid-Complexed Amphotericin B,” <i>J Antimicrob Chemother</i>, 1994, 33(5):907-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/8089064/pubmed" id="8089064" target="_blank">8089064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11801578">
<a name="11801578"></a>Dupont B. Overview of the lipid formulations of amphotericin B. <i>J Antimicrob Chemother</i>. 2002;49(suppl 1):S31-S36. doi:10.1093/jac/49.suppl_1.31<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/11801578/pubmed" id="11801578" target="_blank">11801578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9243032">
<a name="9243032"></a>Edwards JE Jr, Bodey GP, Bowden RA, et al, “International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections,” <i>Clin Infect Dis</i>, 1997, 25(1):43-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/9243032/pubmed" id="9243032" target="_blank">9243032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34599691">
<a name="34599691"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Intensive Care Med.</i> 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/34599691/pubmed" id="34599691" target="_blank">34599691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.doo">
<a name="expert.doo"></a>Expert opinion. Senior Obesity EditorialTeam: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD,BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21258094">
<a name="21258094"></a>Freifeld AG, Bow EJ, Sepkowitz KA, et al; Infectious Diseases Society of America (IDSA). Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2011;52(4):e56-e93. doi:10.1093/cid/cir073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/21258094/pubmed" id="21258094" target="_blank">21258094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27470238">
<a name="27470238"></a>Galgiani JN, Ampel NM, Blair JE, et al; Infectious Diseases Society of America. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of Coccidioidomycosis. <i>Clin Infect Dis</i>. 2016;63(6):e112-e146. doi:10.1093/cid/ciw360<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/27470238/pubmed" id="27470238" target="_blank">27470238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al, “Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,” <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11305476">
<a name="11305476"></a>Herbrecht R, Auvrignon A, Andrès E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. <i>Eur J Clin Microbiol Infect Dis</i>. 2001;20(2):77-82. doi:10.1007/s100960000437<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/11305476/pubmed" id="11305476" target="_blank">11305476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8824978">
<a name="8824978"></a>Hiemenz JW and Walsh TJ, “Lipid Formulations of Amphotericin B: Recent Progress and Future Directions,” <i>Clin Infect Dis</i>, 1996, 22(Suppl 2):133-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/8824978/pubmed" id="8824978" target="_blank">8824978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15845425">
<a name="15845425"></a>Hooshmand-Rad R, Chu A, Gotz V, et al, "Use of Amphotericin B Lipid Complex in Elderly Patients," <i>J Infect</i>, 2005, 50(4):277-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/15845425/pubmed" id="15845425" target="_blank">15845425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17968818">
<a name="17968818"></a>Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2007;45(10):1255-1265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/17968818/pubmed" id="17968818" target="_blank">17968818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kauffman.1">
<a name="Kauffman.1"></a>Kauffman CA. Esophageal candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed September 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9827262">
<a name="9827262"></a>King CT, Rogers PD, Cleary JD, Chapman SW. Antifungal therapy during pregnancy. <i>Clin Infect Dis</i>. 1998;27(5):1151-1160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/9827262/pubmed" id="9827262" target="_blank">9827262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8589135">
<a name="8589135"></a>Kline S, Larsen TA, Fieber L, et al, “Limited Toxicity of Prolonged Therapy With High Doses of Amphotericin B Lipid Complex,” <i>Clin Infect Dis</i>, 1995, 21(5):1154-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/8589135/pubmed" id="8589135" target="_blank">8589135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11847833">
<a name="11847833"></a>Mactal-Haaf C, Hoffman M, Kuchta A. Use of anti-infective agents during lactation, part 3: antivirals, antifungals, and urinary antiseptics.<i> J Hum Lact</i>. 2001;17(2):160-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/11847833/pubmed" id="11847833" target="_blank">11847833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15899731">
<a name="15899731"></a>Malani PN, Depestel DD, Riddell J, Bickley S, Klein LR, Kauffman CA. Experience with community-based amphotericin B infusion therapy. <i>Pharmacotherapy</i>. 2005;25(5):690-697. doi:10.1592/phco.25.5.690.63591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/15899731/pubmed" id="15899731" target="_blank">15899731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30924967">
<a name="30924967"></a>Miller R, Assi M; AST Infectious Diseases Community of Practice. Endemic fungal infections in solid organ transplant recipients-guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. <i>Clin Transplant.</i> 2019;33(9):e13553. doi:10.1111/ctr.13553<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/30924967/pubmed" id="30924967" target="_blank">30924967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26779483">
<a name="26779483"></a>Moghnieh R, El-Rajab N, Abdallah DI, et al. Retrospective analysis on the use of amphotericin B lipid complex in neutropenic cancer patients with suspected fungal infections in lebanon, a single center experience and review of international guidelines. <i>Front Med (Lausanne)</i>. 2016;2:92. doi:10.3389/fmed.2015.00092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/26779483/pubmed" id="26779483" target="_blank">26779483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12490683">
<a name="12490683"></a>Mora-Duarte J, Betts R, Rotstein C, et al, “Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis,” <i>N Engl J Med</i>, 2002, 347(25):2020-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/12490683/pubmed" id="12490683" target="_blank">12490683</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nucci.1">
<a name="Nucci.1"></a>Nucci M, Anaissie E. Treatment and prevention of Fusarium infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19196219">
<a name="19196219"></a>O'Connor N, Borley A. Prospective audit of the effectiveness of hydrocortisone premedication on drug delivery reactions following amphotericin B lipid complex *. <i>Curr Med Res Opin.</i> 2009;25(3):749-754. doi:10.1185/03007990902752753<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/19196219/pubmed" id="19196219" target="_blank">19196219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26679628">
<a name="26679628"></a>Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi: 10.1093/cid/civ933.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/26679628/pubmed" id="26679628" target="_blank">26679628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27365388">
<a name="27365388"></a>Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html. Accessed August 8, 2016.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/27365388/pubmed" id="27365388" target="_blank">27365388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047480">
<a name="20047480"></a>Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2010;50(3):291-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/20047480/pubmed" id="20047480" target="_blank">20047480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15809926">
<a name="15809926"></a>Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. <i>Clin Infect Dis</i>. 2005;40(suppl 6):S401-S408. doi:10.1086/429331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/15809926/pubmed" id="15809926" target="_blank">15809926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25204341">
<a name="25204341"></a>Pilmis B, Jullien V, Sobel J, et al. Antifungal drugs during pregnancy: an updated review. <i>J Antimicrob Chemother</i>. 2015;70(1):14-22. doi: 10.1093/jac/dku355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/25204341/pubmed" id="25204341" target="_blank">25204341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9337444">
<a name="9337444"></a>Rapp RP, Gubbins PO, and Evans ME, “Amphotericin B Lipid Complex,” <i>Ann Pharmacother</i>, 1997, 31(10):1174-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/9337444/pubmed" id="9337444" target="_blank">9337444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12746765">
<a name="12746765"></a>Rex JH, Pappas PG, Karchmer AW, et al, “A Randomized and Blinded Multicenter Trial of High-Dose Fluconazole Plus Placebo Versus Fluconazole Plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects,” <i>Clin Infect Dis</i>, 2003, 36(10):1221-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/12746765/pubmed" id="12746765" target="_blank">12746765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8997484">
<a name="8997484"></a>Sacks GS and Cleary JD, “Nutritional Impact of Lipid-Associated Amphotericin B Formulations,” <i>Ann Pharmacother</i>, 1997, 31(1):121-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/8997484/pubmed" id="8997484" target="_blank">8997484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20616663">
<a name="20616663"></a>Safdar A, Ma J, Saliba F, et al. Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. <i>Medicine (Baltimore)</i>. 2010;89(4):236-244. doi:10.1097/MD.0b013e3181e9441b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/20616663/pubmed" id="20616663" target="_blank">20616663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8838189">
<a name="8838189"></a>Sharkey PK, Graybill JR, Johnson ES, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS.<i> Clin Infect Dis</i>. 1996;22(2):315-321.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/8838189/pubmed" id="8838189" target="_blank">8838189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sigma.Tau.1">
<a name="Sigma.Tau.1"></a>Sigma-Tau Pharmaceuticals manufacturer communication January 3, 2014. Data on file.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10221369">
<a name="10221369"></a>Slain D, “Lipid-Based Amphotericin B for the Treatment of Fungal Infections,” <i>Pharmacotherapy</i>, 1999, 19(3):306-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/10221369/pubmed" id="10221369" target="_blank">10221369</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28203777">
<a name="28203777"></a>Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis. <i>Clin Infect Dis.</i> 2017;64(6):34-65. doi:10.1093/cid/ciw861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/28203777/pubmed" id="28203777" target="_blank">28203777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Adult and Adolescent Opportunistic Infection. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/whats-new</a>. Updated January 18, 2023. Accessed April 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/whats-new-guidelines</a>. Updated September 2, 2022. Accessed April 5, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.4">
<a name="HHS.4"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Adult_OI.pdf</a>. Updated 2021. Accessed February 8, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vazquez.1">
<a name="Vazquez.1"></a>Vazquez JA. Management of candidemia and invasive candidiasis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vanneaux.1">
<a name="Vanneaux.1"></a>Vanneaux V, Proust V, Chéron M, et al. A physical and chemical stability study of amphotericin B lipid complexes (Abelcet) after dilution in dextorse 5%. <i>EJHP Science</i>. 2007; 13(1); 10-13.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9303390">
<a name="9303390"></a>Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. <i>Antimicrob Agents Chemother</i>. 1997;41(9):1944-1948. doi:10.1128/AAC.41.9.1944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/9303390/pubmed" id="9303390" target="_blank">9303390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31588493">
<a name="31588493"></a>Wasmann RE, Smit C, van Dongen EPH, et al. Fixed dosing of liposomal amphotericin B in morbidly obese individuals. <i>Clin Infect Dis</i>. 2020;70(10):2213-2215. doi:10.1093/cid/ciz885<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/31588493/pubmed" id="31588493" target="_blank">31588493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17806045">
<a name="17806045"></a>Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2007;45(7):807-825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/17806045/pubmed" id="17806045" target="_blank">17806045</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11073745">
<a name="11073745"></a>Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. LAmph/ABLC Collaborative Study Group. <i>Clin Infect Dis</i>. 2000;31(5):1155-1163.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/11073745/pubmed" id="11073745" target="_blank">11073745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16304177">
<a name="16304177"></a>Würthwein G, Groll AH, Hempel G, et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. <i>Antimicrob Agents Chemother</i>. 2005;49(12):5092-5098.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/amphotericin-b-lipid-complex-drug-information/abstract-text/16304177/pubmed" id="16304177" target="_blank">16304177</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8724 Version 245.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
